US Generic Drug Market Size | Outlook 2016 - 2021

Imarc

Consulting Services

www.imarcgroup.com

US Generic Drug Market to Reach US$ 141.5 Billion by 2021

Copyright Š 2016 International Market Analysis Research & Consulting (IMARC). All Rights Reserved

Imarc

About IMARC Group

Report Description

www.imarcgroup.com

The International Market Analysis Research and Consulting Group is a leading advisor on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations.

Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.

Imarc

Report Description and Highlights

Report Description

www.imarcgroup.com

US Generic Drug Market to Reach US$ 141.5 Billion by 2021 Generic drugs have low research & development requirements. As a result, the costs involved in developing and manufacturing them are significantly lower than their branded counterparts. This allows generic manufacturers to price their drugs considerably lower compared to branded drugs. This has ultimately enabled the government, third-party payers and patients to save billions of dollars on healthcare expenditures.

A recently released report by IMARC Group titled “US Generic Drug Market – Industry Trends, Competitive Landscape, Opportunities and Outlook” provides a deep insight into the generic drugs market in the US. Over the last three decades, the US generic drug market has experienced robust growth and currently represents the world’s biggest market for generic drugs. From less than 20% of the total prescriptions, generic drugs now account for the majority of the total prescriptions dispensed in the US. The report cites several factors that are currently catalysing the growth of the US generic drug market. One of the major factors that has contributed to the growth of this market is the patent expiry of a number of blockbuster branded drugs. Once branded drugs go off-patent, manufacturers can launch generic versions of these drugs. As these drugs have low research & development requirements, the costs involved in developing and manufacturing them are significantly lower than branded drugs. This allows generic manufacturers to price their drugs considerably lower compared to branded drugs. This has ultimately enabled the government, third-party payers and patients to save billions of dollars on healthcare expenditures. Other growth inducing factors include aging population, increasing prevalence of chronic diseases and incentives offered to physicians and pharmacists to promote generics.

Imarc

Report Description and Highlights

Report Description

www.imarcgroup.com

Browse press release: http://www.imarcgroup.com/us-generic-drug-market According to the report, the market for generic drugs in the US reached values worth US$ 74.5 Billion in 2015, representing a CAGR of 13.3% during 2010-2015. Estimates by IMARC Group further suggest that the market is expected to grow at a CAGR of 11% during 2016-2021 reaching figures worth US$ 141.5 Billion by 2021.

The report has bifurcated the market on the basis of branded and unbranded generics. Currently, unbranded generics dominate the market and account for the majority of the total generic prescription volumes. The report has further segmented the market on the basis of distribution. Some of the key purchasers of generic drugs in the US include Red Oak Sourcing, Walgreens Boots Alliance, McKesson One Stop, Econdisc Contracting Solutions, etc. The report has also provided a detailed competitive landscape analysis covering the key players operating in this market. At present, Teva represents the largest generic manufacturer in the US accounting for around a fifth of the total generic sales. Other major players include: Mylan Labs Inc., Sandoz, Endo/Par and Sun Pharmaceutical.

This report provides a comprehensive insight into the historical and current trends as well as the future prospects of the generic drug market in the US. This study serves as an exceptional tool to understand the sales trends, volume trends, growth, key segments, competitive structure, regulations, major manufacturer, major distributors, top drugs, manufacturing requirements, opportunities and future prospects of the US generic drug market. This report can serve as an excellent guide for manufacturers, consultants, researchers, marketing strategists and all those who plan to foray into the US generic drug market in any form.

Imarc

Report Description and Highlights

Report Description

www.imarcgroup.com

Enquiry for sample report or more details, click here: http://www.imarcgroup.com/enquiry-form/

Table of Contents 1 Research Methodology and Market Definitions 2 Report Summary 3 US Generic Drug Market – Introduction 3.1 What are Generic Drugs?

3.2 Unbranded and Branded Generics 3.3 Authorized Generics 3.4 Commoditized and Specialty Generics 4 Why is the US Generic Drug Market so Lucrative 4.1 Patent Expiry of Blockbuster Drugs 4.2 Significant Price Differential between Generics and Innovator Drugs 4.3 Savings for the Government and Third Party Payers 4.4 Incentives for Dispensing and Prescribing Generic Drugs 4.5 Reimbursement and Lower Copayments 4.6 Biosimilars 5 Global Generic Drug Market 5.1 Current and Historical Market Trends 5.2 Market Breakup by Country: The United States Represents the World’s Biggest Market

Imarc

Report Description and Highlights

Report Description

www.imarcgroup.com

5.3 Market Forecast 5.4 Most Prescribed Generic and Branded Drugs

List of Figures Figure 3 1: Structure of the Pharmaceutical Industry Figure 3 2: Classification of Generic Drugs Figure 4 1: US: Patent Expiry Exposure (in Billion US$), 2009-2018 Figure 4 2: US: Savings from Generic Drugs (in Billion US$), 2005-2015 Figure 5 1: Global: Generic Drug Market: Sales Value (in Billion US$), 2010-2015 Figure 5 2: Global: Generic Drug Market: Sales Volume (in Billion Units), 2010-2015 Figure 5 3: Global: Generic Drug Market: Sales Value Breakup by Country (in %), 2015 Figure 5 4: Global: Generic Drug Market: Sales Volume Breakup by Country (in %), 2015 Figure 5 5: Global: Generic Drug Market Forecast: Sales Value (in Billion US$), 2016-2021 Figure 5 6: Global: Generic Drug Market: Sales Volume (in Billion Units), 2016-2021 Figure 6 1: US: Pharmaceutical Market: Sales Volume (in Billion Units), 2010-2015 Figure 6 2: US: Pharmaceutical Market: Sales Value (in Billion US$), 2010-2015 Figure 6 3: US: Pharmaceutical Market Forecast: Sales Value (in Billion US$), 2016-2021 Figure 6 4: US: Pharmaceutical Market: Sales Volume (in Billion Units), 2016-2021 Figure 6 5: US: Pharmaceutical Market: Sales Volume Breakup of Branded and Generic Drugs (in %), 2010 and 2015

Imarc

Report Description and Highlights

Report Description

www.imarcgroup.com

Figure 6 6: US: Pharmaceutical Market: Sales Value Breakup of Branded and Generic Drugs (in %), 2010 and 2015 Figure 6 9: US: Generic Drug Market: Sales Volume (in Billion Units), 2010-2015 Figure 6 10: US: Generic Drug Market Forecast: Sales Volume (in Billion Units), 2016-2021 Figure 6 7: US: Generic Drug Market: Sales Value (in Billion US$), 2010-2015 Figure 6 8: US: Generic Drug Market Forecast: Sales Value (in Billion US$), 2016-2021 Figure 6 11: US: Generic Drug Market: Market Breakup by Segment (in %), 2010-2015 Figure 7 1: US: Generic Drug Market: Sales Share of Top Players (in %), 2015 Figure 7 2: US: Generic Drug Market: Volume Share of Top Players (in %), 2015 Figure 7 3: US: Generic Drug Market: Volume Share by Distribution (in %), 2015 Figure 7 4: US: Generic Drug Prices as a Percentage of Branded Drug Prices – Based on Number of Competitors Figure 8 1: US: Generic Drug Market: Value Chain Analysis List of Tables Table 4 1: US: Sales and Patent Expiry of Major Drugs Expected to Lose Patent Protection (in Billion US$) Table 4 2: US: Price Differential between Generics and Innovator Drugs (in %) Table 5 1: Sales Volume and Growth in Major Markets, 2015 Table 5 2: Volume Performance of Top Generic Drugs (in Million Prescriptions), 2015

Imarc

Report Description and Highlights

Report Description

www.imarcgroup.com

Table 5 3: Global: Branded Drug Market: Volume Performance of Top Branded Drugs (in Million Prescriptions), 2015 Table 7 1: Sales Performance of Top Players (in Billion US$), 2015 Table 7 2: Volume Performance of Top Players (in Billion Units), 2015 Table 7 3: US: Generics Market: Volume Performance of Top Generic Drugs (in Million Prescriptions), 2015 Table 9 1: US: Overview of Pharmaceutical Regulations

Imarc

Report Description and Highlights

Report Description

www.imarcgroup.com

To buy the complete report or to get a free sample, please contact:

IMARC Group Asia: Email: apac@imarcgroup.com Phone: +91-120-415-5099

IMARC Group North America: Email: america@imarcgroup.com Phone: +1-631-791-1145

IMARC Group Europe, Middle East & Africa: Email: ema@imarcgroup.com Phone: +44-702-409-7331

To know more please visit: http://www.imarcgroup.com/us-generics-market

Imarc

Report Description and Highlights

Report Description

www.imarcgroup.com

Š 2015 IMARC All Rights Reserved This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC).

Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing.

International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication.

IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.

Contact Us

FOR MORE DETAILS Visit us at :

http://www.imarcgroup.com Stay With Us:

TELEPHONE: +91-120-4155099 E-MAIL: sales@imarcgroup.com